J. Weisbort

Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study.

D. Brunner, N. Meshulam, H. Saltz-Rennert, 1987, The American journal of cardiology.

Serum cholesterol and high density lipoprotein-cholesterol in coronary patients and healthy persons.

D. Brunner, J. Bearman, J. Weisbort, 1979, Atherosclerosis.

Lipo- and apolipoproteins in a population survey subset in MONICA-Israel.

D. Brunner, G. Slutzky, J. Weisbort, 2009, Acta medica Scandinavica. Supplementum.

Thromboxane, prostacyclin, beta-thromboglobin, and diabetes mellitus.

D. Brunner, J. Weisbort, J. Klinger, 1984, Clinical therapeutics.

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial).

U. Goldbourt, S. Behar, E. Kaplinsky, 1993, The American journal of cardiology.

Multivariate analysis of the twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study and the usefulness of high density lipoprotein cholesterol percentage.

D. Brunner, N. Meshulam, G. Livshits, 1989, The American journal of cardiology.